IFNA2 and non-small cell lung carcinoma: In NSCLC patients treated with nivolumab, a significantly elevated level of peripheral IFN-α was observed in those with longer PFS, indicating the synergistic effect of regional IFN-α with anti-PD-1 therapy [347].